ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor plus palbociclib (AI plus P) for metastatic breast cancer (MBC) in the PADA-1 trial

ANNALS OF ONCOLOGY

ELSEVIER

1. Pfizer